Who
Phillip Andrew Dennis
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, NovaBridge Biosciences.
In numbers
- Trades disclosed
- 12
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $23K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Jun 2026
- Last trade
- 18 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 21 Sep 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Sold | $5,8288,209 at $0.71 | filing |
| 18 Sep 2026filed 21 Sep 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Sold | $5,8288,209 at $0.71 | filing |
| 17 Sep 2026filed 21 Sep 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Code M | —23,695 | filing |
| 17 Sep 2026filed 21 Sep 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,302 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,302 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Code M | —23,695 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Sold | $5,6068,494 at $0.66 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Sold | $5,6068,494 at $0.66 | filing |
| 17 Jun 2026filed 22 Jun 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Code M | —23,695 | filing |
| 17 Jun 2026filed 22 Jun 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,302 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | NBP NovaBridge Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,302 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | NBP NovaBridge BiosciencesBiotechnology | SEC FORM 4 Code M | —23,695 | filing |
News
No headline names them, or the companies they trade most, lately.